Clinical Trials

GLP-1 receptor agonists are not just making waves in weight management and diabetes care—they’re showing potential in addressing various forms of addiction. By modulating dopamine pathways in the brain, these medications could help reduce cravings and compulsive behaviours across a spectrum of addictions.

For decades, BMI has been the default measure for assessing health risks linked to weight. But while it’s easy to calculate, BMI has serious flaws—it can’t distinguish between fat and muscle, and it ignores fat distribution. Enter the Body Roundness Index (BRI), a newer metric that might finally offer a more precise look at obesity-related health risks.

In a world dominated by convenience, ultra-processed foods (UPFs) have become a staple in many diets. These foods are packaged products containing ingredients designed to extend shelf life and enhance taste. While UPFs make up 60%-70% of the US diet, their health impacts, particularly on cardiovascular disease (CVD), remain under-researched. A recent study, along with […]

Understanding Obstructive Sleep Apnoea (OSA) Obstructive Sleep Apnoea (OSA) is a common sleep disorder where your airway repeatedly gets blocked during sleep, leading to interrupted breathing. This can cause loud snoring, choking or gasping for air, and excessive daytime sleepiness. Untreated OSA can lead to serious health issues like heart disease and stroke. How is […]

The SELECT trial has provided significant insights into the cardiovascular benefits of semaglutide, a GLP-1 receptor agonist, for individuals who are obese or overweight and do not have diabetes. This study aimed to determine whether semaglutide could reduce the incidence of major adverse cardiovascular events (MACE) in this population. Here’s a concise overview of the […]